Berotralstat Production Cost Reports

The report provides a detailed analysis essential for establishing a berotralstat production plant. It encompasses all critical aspects necessary for berotralstat production, including the cost of berotralstat production, berotralstat plant cost, berotralstat production costs, and the overall berotralstat production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a berotralstat production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Berotralstat is a medication that is primarily used in the long-term management of hereditary angioedema. It is primarily used as a prescription medicine to help prevent recurrent swelling attacks in patients suffering from hereditary angioedema (HAE), which is a rare genetic disorder. It is widely used for the prophylactic prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older. It works by reducing the activity of plasma kallikrein, which helps control the excessive production of substances responsible for swelling. It is taken orally and is suitable for routine use, which makes it convenient for patients who require ongoing preventive treatment. In clinical practice, berotralstat support improved quality of life by lowering the frequency and severity of angioedema attacks under regular medical supervision.

The market for berotralstat is predominantly driven by its demand as a long-term treatment to lower the risk of hereditary angioedema (HAE) attacks, which largely supports its market growth. Its application as an oral drug for preventing attacks of hereditary angioedema (HAE), which causes sudden swelling in various parts of the body, also boosts its demand in the pharmaceutical industry.

Its involvement in blocking the enzyme called plasma kallikrein, which helps reduce the frequency of HAE episodes, significantly drives its demand in the medical and healthcare sectors. Growing awareness about rare genetic conditions, improved diagnostic rates, and rising demand for targeted therapies further strengthen its market potential. Technological advancements in drug development, production scalability, supplier dependability, and streamlined global logistics also play a crucial role in shaping the procurement strategies for berotralstat across major pharmaceutical markets. Additionally, industrial Berotralstat procurement is influenced by factors such as the cost and steady availability of major active ingredients, compliance with regulatory frameworks, and safety standards.

Raw Material for Berotralstat Production

According to the berotralstat production plant project report, the major raw materials for berotralstat production include dibenzylamine, cyclopropylcarboxaldehyde, oxalic acid, isopropanol, Boc-pyrazole acid, and hydrochloric acid.

Production Process of Berotralstat

The extensive berotralstat production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of berotralstat hydrochloride begins with the treatment of dibenzylamine with a base, followed by a reductive amination with cyclopropylcarboxaldehyde to form a substituted amine. Then, this amine is reacted with oxalic acid in isopropanol to form the oxalate salt, which is hydrolysed using a base to give the free cyclopropylamine. This intermediate is then coupled with acid (Boc-pyrazole acid) under standard amide coupling conditions to form the core structure of berotralstat as a free base. The free base undergoes an acid-base treatment and is finally reacted with hydrochloric acid in methanol to form berotralstat hydrochloride as the final product.

Berotralstat is a synthetic small molecule that functions as a selective plasma kallikrein inhibitor. It appears as a white to off-white powder in its dihydrochloride salt form. It is generally marketed under the brand name Orladeyo. The molecular formula of the free base compound is C30H26F4N6O, and its molar mass is 562.57 g/mol. The compound is soluble in water at pH levels of 4 or below. It is the first once-daily oral therapy for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients aged 12 years and older. The density of the compound is around 1.38 g/cm3, and its boiling point is around 621.2 degree Celsius. The compound works by binding to plasma kallikrein and inhibiting its proteolytic activity, thereby controlling excess bradykinin generation in patients with hereditary angioedema. The most common side effects associated with the compound include abdominal pain, diarrhoea, vomiting, back pain, and heartburn. Doses higher than the recommended 150 mg once daily may lead to QT prolongation, which is a heart rhythm abnormality.